Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer
November 27, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates
November 14, 2023 08:05 ET
|
Terns Pharmaceuticals, Inc.
Announced global Phase 1 clinical trial design of TERN-701 (allosteric BCR-ABL) for CML with patient screening anticipated in December 2023 and interim top-line data expected in the second half of...
Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023
November 13, 2023 08:05 ET
|
Terns Pharmaceuticals, Inc.
TERN-501 treatment over 12 weeks significantly improved liver fat content and fibro-inflammation in NASH patients, with low rates of gastrointestinal and no cardiovascular adverse events TERN-501...
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
November 09, 2023 08:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
November 03, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity
November 02, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
Phase 1 trial underway for Terns’ first oral GLP-1R agonist candidate for obesity, with 28-day proof of concept data anticipated in 2H24 Oral GLP-1R agonist offers potential for weight loss and...
Terns Pharmaceuticals to Participate in Upcoming Investor Conferences
October 19, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia
October 16, 2023 08:05 ET
|
Terns Pharmaceuticals, Inc.
Investigational New Drug application cleared by U.S. Food and Drug Administration Design leverages insights from partner’s ongoing Phase 1 trial in China that support starting dose that appears safe...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
October 03, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
September 06, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...